^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer

    Excerpt:
    CONTRADICTING EVIDENCE: Targeted Therapy: A nonsteroidal AI and palbociclib may be offered to postmenopausal women with treatment-naive HR-positive MBC, because progression-free survival (PFS) but not overall survival (OS) was improved compared with letrozole alone.
    Secondary therapy:
    Aromatase inhibitor
    DOI:
    10.1200/JCO.2016.67.1487
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Negative Breast Cancer)
    New
    Excerpt:
    Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:...in combination with an aromatase inhibitor…in combination with fulvestrant in women who have received prior endocrine therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

    Excerpt:
    ...Number of Participants According to the Starting Dose of Palbociclib`Duration of Treatment`Number of Participants Who Had Any Palbociclib Dose Reduction`Number of Participants Who Had Any Interruption in Palbociclib Treatment`Number of Participants Who Had Any Delays in Palbociclib Treatment`Number of Participants According to Reasons for Treatment Discontinuation`Number of Participants According to Reasons for Change in Treatment`Progression Free Survival`Objective Response Rate (ORR)`Number of Participants Who Died`Overall Survival (OS)`Number of Participants According to Biomarker Status`Number of Participants With Family History of Breast Cancer`Duration From Breast Cancer Diagnosis to Palbociclib Treatment`Number of Participants According to Stages of Breast Cancer`Number of Participants According to Node Status`Number of Participants According to Menopausal Status`Number of Participants According to Performance Status Based on Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)`Number of Participants According to Metastatic Sites`Number of Participants According to de Novo and Recurrent Disease`Number of Participants According to Therapies Received for Early Breast Cancer`Time Since End of Adjuvant Treatment`Number of Participants According to Supportive Therapies Received for Hormone Receptor Positive / Human Epidermal Growth Factor 2 Negative (HR+/HER2-) Diagnosis`Duration of Supportive Treatments for ABC/MBC`Number of Participants According to Reasons for Regimen Change...
    Trial ID:
    NCT05584644
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

    Excerpt:
    ...- Female patients ≥ 18 years of age diagnosed with hormone receptor-positive/ human epidermal growth factor receptor 2- negative metastatic breast cancer undergoing treatment with Palbociclib combined with aromatase inhibitors (letrozole, exemestane or anastrozole) or fulvestrant as first-line therapy, or in treatment with Palbociclib and fulvestrant as second-line or posterior-line therapy in the metastatic setting; may be using ovarian suppression if the patient is premenopausal....
    Trial ID:
    WEFITTER
    More C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Zhonghua Zhong Liu Za Zhi
    Title:

    [Treatment of palbociclib in hormone receptor positive breast cancer: a real-world study and efficacy prediction model]

    Published date:
    04/23/2023
    Excerpt:
    CONTRADICTING EVIDENCE: We retrospectively analyzed data from 66 HR-positive metastatic breast cancer patients treated with palbociclib and endocrine therapy...The overall response rate was 14.3% (95% CI: 6.7%, 25.4%) and clinical benefit rate was 58.7% (95% CI: 45.6%, 71.0%)....Our report indicates that palbociclib combined with endocrine therapy for HR-positive recurrent metastatic breast cancer is effective and safe...
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.3760/cma.j.cn112152-20210811-00606
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO-BC-I 2020
    Title:

    32P - The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2-negative advanced breast cancer

    Published date:
    05/23/2020
    Excerpt:
    This is the first study to show a significant association between high NLR or PLR values, as measured during CDK 4/6 inhibitor treatment, and lower PFS in HR+ aBC pts.